MP20-20 IDENTIFICATION OF DISSEMINATED TUMOR CELLS IN THE BONE MARROW WITH DISEASE-SPECIFIC MARKERS AT RADICAL PROSTATECTOMY

Abstract

You have accessJournal of UrologyProstate Cancer: Staging I1 Apr 2017MP20-20 IDENTIFICATION OF DISSEMINATED TUMOR CELLS IN THE BONE MARROW WITH DISEASE-SPECIFIC MARKERS AT RADICAL PROSTATECTOMY Emma van der Toom, Stephanie Glavaris, Michael Gorin, James Verdone, Kenneth Pienta, and Heather Chalfin Emma van der ToomEmma van der Toom More articles by this author , Stephanie GlavarisStephanie Glavaris More articles by this author , Michael GorinMichael Gorin More articles by this author , James VerdoneJames Verdone More articles by this author , Kenneth PientaKenneth Pienta More articles by this author , and Heather ChalfinHeather Chalfin More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.652AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Detection of microscopic disseminated disease in prostate cancer has largely been attempted with the study of circulating tumor cells (CTCs). Little is known about the character and clinical significance of disseminated tumor cells (DTCs) that have reached the bone marrow (BM), and prior study has relied on epithelial markers. Yet, it is now known that such markers are also expressed on normal erythroid precursor cells in the BM, thus we developed an assay for prostate-specific DTC identification. METHODS BM aspirates from 12 men with localized and 2 men with metastatic prostate cancer were collected at time of radical prostatectomy (RP) or clinic visit respectively, and processed with the AccuCyte system (RareCyte, Inc., Seattle, WA). Slides were immunostained with DAPI (nuclear), anti-pan-cytokeratin (epithelial), anti-CD45/CD66b/CD11b/CD14/CD34 (white blood cell), and HOXB13 and NKX3.1 (prostate-specific). DTCs were required to have positive prostate channel staining and no white blood cell signal. The DTC count was adjusted for the starting volume of BM and the number of slides stained and spread over. RESULTS DTCs were present in 83% (10/12) of patients at time of RP, with range 0 to 3592 cells/4 mL sample (average 375, median of 39.5). Two patients with metastatic prostate cancer had 52 and 105 DTCs/4mL BM (Table 1). Notably, only 4% of all DTCs were epithelial marker positive (CK+), and only 50% (6/12) of patients had any CK+ DTCs (Fig. 1). CONCLUSIONS The RareCyte system is a promising selection-free system for DTCs detection that does not rely on epithelial markers. Here we report on a novel assay to distinguish DTCs from other cells in the bone marrow using the presumed prostate-specific markers HOXB13 and NKX3.1. The majority of prostate-specific marker positive DTCs did not express the epithelial marker CK. Analyses of the association of DTC count with clinicopathologic variables are ongoing. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e247 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Emma van der Toom More articles by this author Stephanie Glavaris More articles by this author Michael Gorin More articles by this author James Verdone More articles by this author Kenneth Pienta More articles by this author Heather Chalfin More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...